Article

임상진료지침 개발 및 확산에 있어 이해상충문제

배종면 1 , *
Jong-Myon Bae 1 , *
Author Information & Copyright
1제주대학교 의학전문대학원 예방의학교실
1Department of Preventive Medicine, Jeju National University School of Medicine
*제주대학교 의학전문대학원 예방의학교실. 064-755-5567. jmbae@jejunu.ac.kr

ⓒ Copyright 2011 The Korean Society for Medical Ethics. This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: Apr 26, 2011; Accepted: Jun 20, 2011

Published Online: Jun 30, 2011

ABSTRACT

Clinical practice guidelines are systematically developed statements to assist practitioners and patients in making appropriate health care decisions in specific clinical circumstances. The potential influence of industry in the development or dissemination of clinical practice guidelines raises ethical concerns. A review of the development and dissemination of the Surviving Sepsis Campaign guidelines shows that the interaction between the pharmaceutical industry and academic societies can undermine clinical guidelines and harm the industry’s reputation. Thus, it is argued here that the process of developing and disseminating clinical practice guidelines should not be tainted by problems of corporate support and transparency. Furthermore, the process should identify and manage any conflicts of interest and ensure the patient-centeredness of the evaluation of emerging medical evidence.

Keywords: 임상진료지침; 이해상충; 근거중심보건의료; 패혈증; 드로트레코진알파
Keywords: clinical practice guidelines; conflicts of interest; evidence-based practice; Sepsis; Drotrecogin Alfa Activated